Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
Oncology Pipeline with Extensive Biomarker and Companion Diagnostic Program. ... Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures ...
Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...
The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs.
Autogene cevumeran is an investigational mRNA vaccine being developed jointly by BioNTech and Genentech as an adjuvant therapy in cancer treatment to prevent cancer recurrence following surgery. [ 1 ] [ 2 ] [ 3 ]
Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer Phase III data from the CLL11 study to ...
oncology: Opdivo 7570 5763 6 pembrolizumab: oncology: Keytruda 7171 3809 7 etanercept: rheumatoid arthritis: Enbrel 7126 7885 8 trastuzumab: breast cancer: Herceptin 6981 7013 9 bevacizumab: colon cancer: Avastin 6847 6686 10 rituximab: non-Hodgkin's lymphoma: Rituxan, MabThera 6750 7298 11 rivaroxaban: anticoagulant: Xarelto 6589 6234 12 ...
The implant was approved by the U.S. health regulator in 2021 to treat a chronic disorder that caused blurred vision. The following year, Genentech voluntarily recalled the implant following test ...